Eli Lilly wins FDA accelerated approval for lymphoma therapy (NYSE:LLY)

Eli Lilly and Company Research Laboratories. Lilly makes Medicines and Pharmaceuticals.

jetcityimage/iStock Editorial via Getty Images

The oncology division of Eli Lilly (NYSE:LLY) announced Friday that the FDA greenlighted its Bruton’s tyrosine kinase (BTK) inhibitor Jaypirca as a late-line option for certain patients with mantle cell lymphoma (MCL), a rare blood cancer.

Source link

5 Trading strategies to make money

Looking to boost your trading profits?

Get you copy of our FREE Ebook Now !!!